Jefferies Group LLC set a $40.00 target price on Axovant Sciences Ltd. (NYSE:AXON) in a report released on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other analysts also recently issued reports on the stock. BidaskClub downgraded shares of Axovant Sciences from a hold rating to a sell rating in a research report on Saturday, August 19th. Zacks Investment Research downgraded shares of Axovant Sciences from a hold rating to a sell rating in a research report on Tuesday, July 11th. Cowen and Company reissued an outperform rating and issued a $30.00 price target on shares of Axovant Sciences in a research report on Wednesday, June 21st. CIBC lifted their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an outperform rating in a research report on Wednesday, June 14th. Finally, Oppenheimer Holdings, Inc. lifted their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an outperform rating in a research report on Wednesday, June 14th. Three analysts have rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $27.75.

Axovant Sciences (NYSE:AXON) traded up 0.05% during trading on Friday, reaching $19.55. 577,451 shares of the company were exchanged. Axovant Sciences has a 52-week low of $11.01 and a 52-week high of $26.49. The firm’s market cap is $2.10 billion. The firm has a 50-day moving average of $22.21 and a 200-day moving average of $19.71.

Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.12. On average, equities analysts forecast that Axovant Sciences will post ($2.41) EPS for the current year.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/26/axovant-sciences-ltd-axon-given-a-40-00-price-target-at-jefferies-group-llc.html.

A number of institutional investors have recently bought and sold shares of the company. Legal & General Group Plc increased its position in Axovant Sciences by 20.2% in the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after buying an additional 1,168 shares in the last quarter. Bank of America Corp DE increased its position in Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares in the last quarter. Russell Investments Group Ltd. increased its position in Axovant Sciences by 38.5% in the second quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock worth $233,000 after buying an additional 2,789 shares in the last quarter. Voya Investment Management LLC purchased a new position in Axovant Sciences during the second quarter worth about $323,000. Finally, Laurion Capital Management LP purchased a new position in Axovant Sciences during the second quarter worth about $336,000. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.